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Allocated to control condition n 
=63 
 
Randomized 
n = 141 
 
Allocated to intervention n =78 
  
Followed n = 78  
Lost to follow-up n = 0 
 
 
Followed n = 63 
Lost to follow-up n = 0 
 
 
With primary outcome n = 75 
Analysed n =71 
Excluded from analysis n =7 
Reasons: 
4 not sufficient baseline data 
1 not sufficient intervention data 
2 not sufficient both periods 
 
With primary outcome n = 56 
Analysed n =52 
Excluded from analysis n =8 
Reasons: 
4 not sufficient baseline data 
3 not sufficient intervention data 
1 not sufficient both periods 
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Followed n = 75 
Lost to follow-up n = 1 
Reasons: 
1 discharged to GP 
 
 
Followed n = 55 
Lost to follow-up n = 4 
Reasons: 
2 discharged to GP 
1 died 
1 not in community 
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Followed n=74 
Lost to 6m follow-up n = 4 
Reasons: 
1 dead (during intervention period)  
3 discharged from services 
 
 
 
 
Followed n=58 
Lost to 6m follow-up n = 5 
Reasons: 
1 withdrawn (baseline)  
2 withdrew (baseline) 
1 moved abroad (during 6m follow-up) 
1 not in community  
 
 
 With primary outcome n = 61 
Analysed n =58 
Excluded from analysis n =16 
Reasons: 
5 no depot data in one or both 
periods  
3 not sufficient baseline data 
6 not sufficient follow-up data 
2 not sufficient both periods 
 
With primary outcome n = 45 
Analysed n =41 
Excluded from analysis n =17 
Reasons: 
5 no depot data in one or both 
periods  
1 not sufficient baseline data 
9 not sufficient follow-up data 
2 not sufficient both periods 
1 oral medication only 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With primary outcome n = 66 
Analysed n =66 
Excluded from analysis n =9 
Reasons: 
3 no depot data 
3 not sufficient depot data 
3 oral medication only 
 
With primary outcome n = 50 
Analysed n =49 
Excluded from analysis n =6 
Reasons: 
1 no depot data 
2 not sufficient depot data 
3 oral medication only 
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Figure 1 Consort diagram illustrating participant flow across the different stages of the trial 
 Table 1 Socio-demographic and clinical characteristics at baseline, end of intervention, and 6- and 24-month follow-ups. 
 
 Baseline  End of Intervention 6-month follow-up 24-month follow-up 
 Incentives 
(N=78) 
 
Control 
(N = 63) 
 
Incentives 
(N = 77) 
 
Control 
(N = 60) 
Incentives 
(N =76) 
 
Control 
(N = 60) 
Incentives 
(N = 77) 
 
Control 
(N = 59) 
mean or n SD 
or 
% 
mea
n or 
n 
SD or 
% 
mean 
or n 
SD 
or % 
mean 
or n 
SD 
or % 
mean 
or n 
SD or 
% 
mean 
or n 
SD 
or % 
mean 
or n 
SD 
or % 
mean 
or n 
SD or 
% 
Demographics                 
Age (years) 44.4 9.6 42.7 10.2 45.2 9.3 43.3 10.0 45.6 9.3 43.7 10.0 47.2 9.3 45.5 9.9 
Male sex 59 76% 46 73% 59 76% 45 76% 58 76% 46 77% 59 77% 45 76% 
Ethnicity    
 
 
 
 
            
White 49 63% 34 57% 49 63% 33 56% 47 62% 34 57% 48 62% 33 56% 
Black 17 22% 14 23% 17 22% 14 24% 17 22% 14 23% 17 22% 14 24% 
Asian 5 6% 4 7% 5 6% 4 7% 5 7% 4 7% 5 6% 4 7% 
Mixed and other 7 9% 8 13% 7 9% 8 14% 7 9% 8 13% 7 9% 8 14% 
Living situation                  
Married/co-habiting  8 10% 10 16% 8 10% 7 12% 6 8% 8 13% 12 16% 9 15% 
Independent accommodation  53 68% 49 83% 53 68% 50 85% 52 68% 47 81% 48 64% 45 80% 
Living alone 41 62% 34 62% 43 55% 35 59% 40 63% 34 64% 44 60% 33 69% 
Paid employment (any) 3 4% 1 2% 4 5% 0 0% 4 5% 2 3% 4 5% 1 2% 
Receiving benefits  76 99% 58 100% 70 97% 54 98% 70 97% 57 97% 68 96% 48 100% 
Diagnosis                  
Schizophrenia  61 78% 52 82% 56 81% 45 83% 57 75% 45 75% 56 73% 45 76% 
Schizo-affective disorders  9 12% 8 12% 8 12% 5 9% 11 14% 11 18% 11 14% 7 12% 
Bipolar affective disorder  6 8% 1 2% 4 6% 3 6% 5 7% 3 5% 5 7% 4 7% 
Other psychosis  2 2% 1 2% 1 1% 0 0% 2 3% 0 0% 1 1% 0 0% 
Other diagnosis  0 0% 1 2% 0 0% 1 2% 1 1% 1 2% 3 1% 3 5% 
Clinical history                  
Duration of illness (years)  18.2 8.6 17.3 8.5 19.2 8.6 18.3 8.6 19.9 8.6 18.8 8.5 21.2 8.6 20.5 8.5 
Number of psychiatric 
hospitalisations over  assessment 
period 
0.9 2.7 59 0.6 0.7 1.4 0.6 1.4 0.3 0.7 0.2 0.6 0.9 2.3 0.5 1.2 
  
Table 2 Treatment cycles during baseline, intervention period, during the two follow-up periods. 
Depot cycle 
Baseline End of Intervention 1-6m Follow-up 7-24m Follow-up 
Incentives Control Incentives Control Incentives Control Incentives Control 
N % N % N % N % N % N % N % N % 
1/52 4 5.6 3 5.5 2 2.7 1 1.8 2 3.3 3 6.7 3 4 1 2 
2/52 50 69.4 34 61.8 51 68.0 29 51.8 38 62.3 20 32.8 44 63 24 44 
3/52  5 6.9 2 3.6 4 5.3 3 5.4 4 6.6 2 4.5 3 7 1 2 
4/52 12 16.7 13 23.6 13 17.3 18 32.1 11 18.0 13 28.9 11 16 20 37 
Variable 1 1.4 3 5.5 5 6.7 5 8.9 6 9.8 7 15.6 7 10 8 15 
Total 72 100 55 100 75 100 56 100 61 100 45 100 70 100 54 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 3 Adherence by treatment cycle at baseline, during the intervention period, and during both follow-up periods.  
 
Note:n/a = not applicable 
 
 
 
Treatment 
cycle 
Baseline period (N=123) Intervention period (N=123) 1-6-month follow-up (N=110) 7-24-month follow-up (N=110) 
Incentives 
N=71 
Control, 
(N=52) 
Incentives 
(N=71) 
Control, 
(N=52) 
Incentives  
(N=66) 
Control 
(N=54) 
Incentives  
(N=66) 
Control 
(N=54) 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
1/52 2 54% 1 45% 2 82% 1 49% 3 76% 3 64% 3 78% 1 85% 
2/52 49 67% 27 68% 49 83% 27 74% 41 71% 23 74% 41 67% 24 73% 
3/52 4 76% 3 66% 4 97% 3 44% 4 77% 2 83% 5 74% 1 77% 
4/52 12 76% 16 66% 12 92% 16 73% 13 71% 20 74% 11 66% 18 73% 
5/52 n/a n/a n/a n/a n/a n/a n/a n/a 1 71% 0 n/a n/a n/a n/a n/a 
Variable cycle 4 60% 5 62% 4 72% 5 72% 4 59% 6 87% 6 68% 6 75% 
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Table 4 Primary and secondary outcomes at baseline, end of intervention, and 6- and 24-months follow-ups. 
  Incentives  Control      
 Period 
n* 
74†/75¥ 
Number (%)  
or Means (SD) 
n* 
58†/56¥ 
Number (%) or 
Means (SD) 
Type of effect 
estimate 
Adjusted effect estimate 
(intervention vs. control) P-value ICC∫ 
Primary outcome 
Adherence (percentage) 
to depot medication 
Baseline 72 69% (16%) 55 67% (16%)     
 
12-month 
intervention 
75 85% (15%) 56 71% (22%)   Difference in means‡ 11.5% (3.9% to 19.0%)§ 0.0003 0.28 
 
1-6-month follow-
up 
58 70% (24%) 41 77% (19%) Difference in means‡ -7.4% (-17.0% to 2.1%) 0.127 0.175 
 
7-24-month follow-
up 
66 68% (21%) 50 74% (19%) Difference in means -5.7% (-13.1% to 1.7%) 0.130 n/a 
Secondary outcomes 
Achieving at least 95% 
adherence versus not 
Baseline 72 5 (7%) 55 1 (2%)     
12-month 
intervention 
75 21 (28%) 56 3 (5%) Odds ratio‡ 8.21 (2.00 to 33.67) 0.003 0.04 
1-6-month follow-
up 
66 5 (8%) 54 9 (17%) Odds ratio‡ 0.42 (0.11 to 1.61) 0.205 <0.001 
7-24-month follow-
up 
66 4 (6%) 50 5 (10%) Odds ratio 0.42 (0.06 to 3.02) 0.392 0.42 
At least one psychiatric 
hospital admission 
Baseline 78 14 (19%) 60 10 (17%)     
12-month 
intervention 
78 15 (19%) 59 14 (24%)     
 
1-6-month follow-
up 
74 15 (20%) 58 8 (14%)     
 
7-24-month follow-
up 
77 24 (31%) 60 10 (17%)     
At least one suicide 
attempt versus none 
Baseline 78 9 (12%) 59 7 (12%)     
12-month 
intervention 
77 8 (10%) 58 4 (7%)     
 
1-6-month follow-
up 
73 3 (4%) 58 3 (5%)     
 
7-24-month follow-
up 
75 5 (7%) 58 3 (5%)     
At least one violent 
incident versus none 
Baseline 77 15 (20%) 60 10 (17%)     
12-month 
intervention 
77 10 (13%) 58 7 (12%)     
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1-6-month follow-
up 
73 4 (6%) 58 3 (5%)     
 
7-24-month follow-
up 
75 11 (15%) 58 7 (12%)     
At least one police 
arrest versus none 
Baseline 77 13 (18%) 60 9 (16%)     
12-month 
intervention 
77 10 (13%) 60 10 (17%)     
 
1-6-month follow-
up 
73 6 (8%) 58 3 (5%)     
 
7-24-month follow-
up 
75 14 (19%) 58 10 (17%)     
 
 
*n is the number of patients in either group with both a baseline and follow up period for the specified outcome 
† Number of patients during 6-month follow-up: Excludes 9 patients on whom no data were collected during the 6 month follow up period: 2 who withdrew immediately after randomisation and 1 who 
was withdrawn as was not being prescribed depot medication, 1 who died during the intervention period, 2 who were discharged during the intervention period, 1 who was discharged during the 6 
follow-up period, 1 who moved abroad during follow up and 1 who was out of the community for all of the follow up period. 
¥ Number of patients during 24-month follow-up. Excludes 4 patients who were lost to follow-up before the start of the 6 months follow-up period. Of the remaining 137 patients, 5 were lost during the 6 
month follow up and a further 5 were lost to follow-up during the final phase of the study. Four patients lost during the 6-month follow up returned to the study. 
‡Each model was adjusted for baseline measure of outcome, MINI score category (low vs. high) and average treatment cycle during baseline, and includes a random effect for team.  
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Table 5 Sensitivity analysis of primary outcome at the two follow-up periods 
Note: * Simple linear regression model including only a fixed effect for intervention versus control. Clustering by team ignorable as the ICC was -0.05; ** Linear mixed effects model including only a fixed effect for 
intervention versus control. The model-based ICC was <0.001. 
 
 1-6-month follow-up 7-24-month follow-up 
 Analysis population N 
Difference in 
mean adherence 95% confidence interval p-value N 
Difference in mean 
adherence 
95% confidence 
interval p-value 
Main analysis: all participants with ≥ 4 months’ 
depot data  108 -6.2% -13.1% to 0.7% 0.078 116 -5.7%* -13.1% to 1.7% 0.130 
All participants as above, setting adherence to 
100% for those discharged to GP 130 -5.0% -14.7 % to 4.7% 0.316 119 -6.2%* -13.6% to 1.1% 0.097 
All participants as above but setting adherence to 
0% for refusers  112 -4.9% -14.3% to 4.2% 0.312 124 -6.4%** -15.0% - 2.1% 0.142 
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Table 2 Treatment cycles during baseline, intervention period, during the two follow-up periods. 
Depot cycle 
Baseline End of Intervention 1-6m Follow-up 7-24m Follow-up 
Incentives Control Incentives Control Incentives Control Incentives Control 
N % N % N % N % N % N % N % N % 
1/52 4 5.6 3 5.5 2 2.7 1 1.8 2 3.3 3 6.7 3 4 1 2 
2/52 50 69.4 34 61.8 51 68.0 29 51.8 38 62.3 20 32.8 44 63 24 44 
3/52  5 6.9 2 3.6 4 5.3 3 5.4 4 6.6 2 4.5 3 7 1 2 
4/52 12 16.7 13 23.6 13 17.3 18 32.1 11 18.0 13 28.9 11 16 20 37 
Variable 1 1.4 3 5.5 5 6.7 5 8.9 6 9.8 7 15.6 7 10 8 15 
Total 72 100 55 100 75 100 56 100 61 100 45 100 70 100 54 100 
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Table 3 Adherence by treatment cycle at baseline, during the intervention period, and during both follow-up periods.  
 
Note:n/a = not applicable 
 
 
 
Treatment 
cycle 
Baseline period (N=123) Intervention period (N=123) 1-6-month follow-up (N=110) 7-24-month follow-up (N=110) 
Incentives 
N=71 
Control, 
(N=52) 
Incentives 
(N=71) 
Control, 
(N=52) 
Incentives  
(N=66) 
Control 
(N=54) 
Incentives  
(N=66) 
Control 
(N=54) 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
N Mean 
adherence 
1/52 2 54% 1 45% 2 82% 1 49% 3 76% 3 64% 3 78% 1 85% 
2/52 49 67% 27 68% 49 83% 27 74% 41 71% 23 74% 41 67% 24 73% 
3/52 4 76% 3 66% 4 97% 3 44% 4 77% 2 83% 5 74% 1 77% 
4/52 12 76% 16 66% 12 92% 16 73% 13 71% 20 74% 11 66% 18 73% 
5/52 n/a n/a n/a n/a n/a n/a n/a n/a 1 71% 0 n/a n/a n/a n/a n/a 
Variable cycle 4 60% 5 62% 4 72% 5 72% 4 59% 6 87% 6 68% 6 75% 
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